SAB Biotherapeutics (SABS) Income from Continuing Operations (2021 - 2026)

SAB Biotherapeutics has reported Income from Continuing Operations for 6 years, with the latest figure at 19013284.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations fell 76.39% year-over-year to 19013284.0; the trailing twelve-month figure through Mar 2026 stood at 55996110.0 (down 45.8% YoY), and the FY2025 full-year result was 47761995.0, down 13.87% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 19013284.0, down from 15132954.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 985863.0 in Q1 2022, with the low at 22856763.0 in Q4 2023.
• Historically, Income from Continuing Operations has averaged 9431657.88 across 5 years, with a median of 7848966.0 in 2022.
• Annual changes were most pronounced in 2023 — Income from Continuing Operations sank 845.93% — and 2024, when it jumped 56.5%.
• SAB Biotherapeutics' Income from Continuing Operations stood at 7848966.0 in 2022, then slumped by 191.21% to 22856763.0 in 2023, then surged by 56.5% to 9943342.0 in 2024, then slumped by 52.19% to 15132954.0 in 2025, then slipped by 25.64% to 19013284.0 in 2026.
• The last three Income from Continuing Operations figures came in at 19013284.0 (Q1 2026), 15132954.0 (Q4 2025), and 12067028.0 (Q3 2025), per Business Quant data.